Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma (MM)

Interventions: Drug: Bortezomib
Drug: Dexamethasone
Drug: Lenalidomide

First Posted Date: 2013-08-08

Last Posted Date: 2024-05-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT01919086

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 3 locations

Quit IT: Development of a Web-based, 3D Coping Skills Game to Increase Self-Efficacy for Maintaining Smoking Abstinence Following Hospitalization

Not Applicable

Completed

Conditions: Tobacco Use Cessation

Interventions: Other: web-based video game (Quit IT)
Behavioral: Questionnaires
Behavioral: Evaluation Interview

First Posted Date: 2013-08-05

Last Posted Date: 2014-12-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 20

Registration Number: NCT01915836

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative

Phase 1

Completed

Conditions: Sarcoma
Melanoma
Carcinoma
Myeloma
Lymphoma

Interventions: Radiation: [18F]-SKI-249380
Procedure: PET/CT scan
Other: Blood draws

First Posted Date: 2013-08-05

Last Posted Date: 2020-04-27

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT01916135

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Phase 2

Terminated

Conditions: Bladder Cancer

Interventions: Drug: Gemcitabine
Drug: Carboplatin
Drug: Panitumumab
Procedure: radical cystectomy

First Posted Date: 2013-08-05

Last Posted Date: 2016-02-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 4

Registration Number: NCT01916109

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 2 locations

Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status

Early Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Fluorestradiol (FES)
Procedure: PET/CT Imaging

First Posted Date: 2013-08-05

Last Posted Date: 2024-04-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 54

Registration Number: NCT01916122

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: Regorafenib
Drug: 5-Fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin

First Posted Date: 2013-08-01

Last Posted Date: 2020-05-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 39

Registration Number: NCT01913639

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States

and more 2 locations

Person-Centered Oncology Care and Choices (P-COCC): Piloting and Initial Randomized Testing of a Combined Values Narrative Interview and Video Education Advance Care Planning Program in Gastrointestinal Oncology Patients

Not Applicable

Completed

Conditions: Advanced Gastrointestinal Cancer

Interventions: Behavioral: single pilot interview
Behavioral: usual care
Behavioral: goals-of-care (GOC) video
Behavioral: goals-of-care (GOC) video and narrative question
Behavioral: Part 2

First Posted Date: 2013-07-30

Last Posted Date: 2020-01-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 178

Registration Number: NCT01912131

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

Phase 2

Active, not recruiting

Conditions: T Cell Non-Hodgkin Lymphoma

Interventions: Other: High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin

First Posted Date: 2013-07-26

Last Posted Date: 2024-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 47

Registration Number: NCT01908777

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 6 locations

Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Radiation: Stereotactic Body Radiation Therapy (SBRT)
Drug: cisplatin or carboplatin-based

First Posted Date: 2013-07-16

Last Posted Date: 2024-10-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 39

Registration Number: NCT01899989

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 5 locations

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: LGX818

First Posted Date: 2013-07-10

Last Posted Date: 2024-07-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 7

Registration Number: NCT01894672

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy